Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorasidenib PK in Severe Hepatic Impairment
NCT07250633Phase 1Recruiting
- Sponsor
- Servier
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorasidenib in glioma (2 arms), sponsored by Servier. Primary endpoints: Maximum observed plasma concentration at Day 43, Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration at Day 43 and 6 more. Started Apr 2026; status: recruiting.
02
Drugs
vorasidenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07250633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250633.